Bill Haney, Skyhawk CEO (Dave Pedley/Getty Images for SXSW)

Bill Haney adds an­oth­er $133M to Sky­hawk's cof­fers, as the RNA start­up guns for the clin­ic

A few years af­ter be­com­ing one of the first ma­jor biotechs out to drug RNA with small mol­e­cules, se­r­i­al en­tre­pre­neur and film­mak­er Bill Haney is reel­ing in an­oth­er $133 mil­lion for Sky­hawk Ther­a­peu­tics. And it sounds like he’s got the S-1 pa­pers in his back pock­et.

Sky­hawk un­veiled the lat­est round led by Fi­deli­ty Man­age­ment and Re­search on Tues­day morn­ing, which Haney says is like­ly the com­pa­ny’s last ven­ture round be­fore go­ing pub­lic. Oth­er big name in­vestors like Great­Point Ven­tures and Rock Springs Cap­i­tal al­so chipped in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.